NCT05877222View on ClinicalTrials.gov

A Phase 1 Trial to Investigate the Biological Equivalence of 5 × 10 mg Tablets and 2 × 25 mg Tablets of Daridorexant in Healthy Male and Female Japanese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

June 23, 2023

Primary Completion Date

August 4, 2023

Study Completion Date

August 4, 2023

Conditions
Healthy
Interventions
DRUG

Daridorexant 10 mg

Daridorexant will be available as film-coated tablets for oral administration formulated at strengths of 10 mg.

DRUG

Daridorexant 25 mg

Daridorexant will be available as film-coated tablets for oral administration formulated at strengths of 25 mg.

Trial Locations (1)

92801

Anaheim Clinical Trials, Anaheim

Sponsors
All Listed Sponsors
lead

Idorsia Pharmaceuticals Ltd.

INDUSTRY